Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriMix mRNA in Early Breast Cancer
NCT03788083Phase 1Unknown
- Sponsor
- UZ Brussel
- Start
- Nov 2018
- Primary completion
- Sep 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, single-blind trial of Trimix in breast cancer (4 arms), sponsored by UZ Brussel. Primary endpoint: Number of participants with treatment-related adverse events at 2 years. Status: unknown.
02
Drugs
Trimix
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03788083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03788083.